Trial Profile

Evaluation of Safety and Efficacy of Raltegravir/Darunavir Combination in Antiretroviral-Naive Patients.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary) ; Darunavir; Ritonavir
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms RADAR

Most Recent Events

05 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
30 Jun 2013 Forty-eight week results presented at the 7th International AIDS Society Conference on HIV Pathogenesis and Treatment.
31 Aug 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com